Four-year Rebif results published in Neurology

Serono (SRA) reported 4-year results of the PRISMS(3) trial of its Rebif interferon beta-1a in patients with relapsing remitting multiple sclerosis (RRMS) showing that patients who received Rebif for all 4 years had significantly increased time to first relapse and a slower increase in burden of disease compared to placebo. ...